Evaxion Biotech Increases Share Capital Following Warrant Exercise

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.Evaxion Biotech ( (EVAX) ) has shared an announcement. On November 4, 2025, Evaxion Biotech announced a share capital increase following the exercise of certain investor warrants. This resulted in the issuance of 1,875,000 ordinary shares, raising the company’s share capital to nominal DKK 104,252,689. The capital increase, registered with the Danish Business Authority, reflects a cash consideration of USD 101,625. This move is part of Evaxion’s strategic efforts to strengthen its financial position and potentially enhance its market presence. The most recent analyst rating on (EVAX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page. Spark’s Take on EVAX Stock According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral. Evaxion Biotech’s overall score is driven by strong earnings call highlights, including strategic partnerships and promising clinical results. However, financial instability and valuation concerns weigh heavily, reflecting the company’s ongoing challenges in achieving profitability. To see Spark’s full report on EVAX stock, click here. More about Evaxion Biotech Evaxion Biotech is a company operating in the biotechnology industry, focusing on creating advanced software for the development of novel immune therapies and vaccines. Average Trading Volume: 1,599,481 Technical Sentiment Signal: Sell Current Market Cap: $34.49M For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.